Literature DB >> 25433625

Annual rates of decline in child, maternal, HIV, and tuberculosis mortality across 109 countries of low and middle income from 1990 to 2013: an assessment of the feasibility of post-2015 goals.

Stéphane Verguet1, Ole Frithjof Norheim2, Zachary D Olson3, Gavin Yamey4, Dean T Jamison4.   

Abstract

BACKGROUND: Measuring a country's health performance has focused mostly on estimating levels of mortality. An alternative is to measure rates of decline in mortality, which are more sensitive to changes in health policy than are mortality levels. Historical rates of decline in mortality can also help test the feasibility of future health goals (eg, post-2015). We aimed to assess the annual rates of decline in under-5, maternal, tuberculosis, and HIV mortality over the past two decades for 109 low-income and middle-income countries.
METHODS: For the period 1990-2013, we estimated annual rates of decline in under-5 mortality (deaths per 1000 livebirths), the maternal mortality ratio (deaths per 100 000 livebirths), and tuberculosis and HIV mortality (deaths per 100 000 population per year) using published data from UNICEF and WHO. For every 5-year interval (eg, 1990-95), we defined performance as the size of the annual rate of decline for every mortality indicator. Subsequently, we tested the feasibility of post-2015 goals by estimating the year by which countries would achieve 2030 targets proposed by The Lancet's Commission on Investing in Health (ie, 20 deaths per 1000 for under-5 mortality, 94 deaths per 100 000 for maternal mortality, four deaths per 100 000 for tuberculosis mortality, and eight deaths per 100 000 for HIV mortality) at observed country and aspirational best-performer (90th percentile) rates.
FINDINGS: From 2005 to 2013, the mean annual rate of decline in under-5 mortality was 4·3% (95% uncertainty interval [UI] 3·9-4·6), for maternal mortality it was 3·3% (2·5-4·1), for tuberculosis mortality 4·1% (2·8-5·4), and for HIV mortality 2·2% (0·1-4·3); aspirational best-performer rates per year were 7·1% (6·8-7·5), 6·3% (5·5-7·1), 12·8% (11·5-14·1), and 15·3% (13·2-17·4), respectively. The top two country performers were Macedonia and South Africa for under-5 mortality, Belarus and Bulgaria for maternal mortality, Uzbekistan and Macedonia for tuberculosis mortality, and Namibia and Rwanda for HIV mortality. At aspirational rates of decline, The Lancet's Commission on Investing in Health target for under-5 mortality would be achieved by 50-64% of countries, 35-41% of countries would achieve the 2030 target for maternal mortality, 74-90% of countries would meet the goal for tuberculosis mortality, and 66-82% of countries would achieve the target for HIV mortality.
Copyright © 2014 Verguet et al. Open Access article distributed under the terms of CC BY-NC-SA. Published by .. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25433625     DOI: 10.1016/S2214-109X(14)70316-X

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN: 2214-109X            Impact factor:   26.763


  12 in total

1.  Achieving a "Grand Convergence" in Global Health by 2035: Rwanda Shows the Way Comment on "Improving the World's Health Through the Post-2015 Development Agenda: Perspectives From Rwanda".

Authors:  Gavin Yamey; Sara Fewer; Naomi Beyeler
Journal:  Int J Health Policy Manag       Date:  2015-07-29

2.  How Has the Lower Boundary of Human Mortality Evolved, and Has It Already Stopped Decreasing?

Authors:  Marcus Ebeling
Journal:  Demography       Date:  2018-10

3.  Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model.

Authors:  Ruth Young; Tewodros Bekele; Alexander Gunn; Nick Chapman; Vipul Chowdhary; Kelsey Corrigan; Lindsay Dahora; Sebastián Martinez; Sallie Permar; Johan Persson; Bill Rodriguez; Marco Schäferhoff; Kevin Schulman; Tulika Singh; Robert F Terry; Gavin Yamey
Journal:  Gates Open Res       Date:  2018-08-22

4.  Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

5.  Are global and regional improvements in life expectancy and in child, adult and senior survival slowing?

Authors:  Ryan J Hum; Stéphane Verguet; Yu-Ling Cheng; Anita M McGahan; Prabhat Jha
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

6.  Mexico's path towards the Sustainable Development Goal for health: an assessment of the feasibility of reducing premature mortality by 40% by 2030.

Authors:  Eduardo González-Pier; Mariana Barraza-Lloréns; Naomi Beyeler; Dean Jamison; Felicia Knaul; Rafael Lozano; Gavin Yamey; Jaime Sepúlveda
Journal:  Lancet Glob Health       Date:  2016-08-30       Impact factor: 26.763

7.  Health insurance is important in improving maternal health service utilization in Tanzania-analysis of the 2011/2012 Tanzania HIV/AIDS and malaria indicator survey.

Authors:  Stephen M Kibusi; Bruno Fokas Sunguya; Eunice Kimunai; Courtney S Hines
Journal:  BMC Health Serv Res       Date:  2018-02-13       Impact factor: 2.655

Review 8.  Transformative Innovations in Reproductive, Maternal, Newborn, and Child Health over the Next 20 Years.

Authors:  Cyril M Engmann; Sadaf Khan; Cheryl A Moyer; Patricia S Coffey; Zulfiqar A Bhutta
Journal:  PLoS Med       Date:  2016-03-02       Impact factor: 11.069

9.  Is the sustainable development goal target for financial risk protection in health realistic?

Authors:  Stéphane Verguet; Addis Tamire Woldemariam; Warren N Durrett; Ole F Norheim; Margaret E Kruk
Journal:  BMJ Glob Health       Date:  2017-09-28

10.  New approaches to ranking countries for the allocation of development assistance for health: choices, indicators and implications.

Authors:  Trygve Ottersen; Karen A Grépin; Klara Henderson; Crossley Beth Pinkstaff; Ole Frithjof Norheim; John-Arne Røttingen
Journal:  Health Policy Plan       Date:  2018-02-01       Impact factor: 3.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.